Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT)

Clinical Nephrology

Volumn 48, Issue 6, 1997, Pages 337-340

  Zazgornik, J ^a,c   Biesenbach, G ^a   Forstenlehner, M ^a   Stummvoll, K ^b  

^a II Medizinische Abteilung   (Austria)

^b ELISABETHINEN HOSPITAL   (Austria)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Antihypertensive drugs; Hypertension; Renal replacement therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUSTRIA; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; QUESTIONNAIRES; RENAL DIALYSIS;

EID: 0030695879     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Aurell M, Delin K, Herlitz H, Mulec H 1982 Captopril treatment in hypertensive dialysis patients. Scand J Urol Nephrol 16: 251-256
2. Biesenbach G, Janko O, Zazgornik J 1994 Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 9: 1097-1102
3. Biesenbach G, Zazgornik J 1996 Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care 19: 625-628
4. Björk S, Mulec H, Johnsen SA, Norden G, Aurell M 1992 Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304: 339-343
5. Charra B, Calemard E, Cuche M, Laurent G 1983 Control of hypertension and prolonged survival on maintenance hemodialysis. Nephron 33: 96-99
6. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G 1992 Survival as an index of adequacy of dialysis. Kidney Int 41: 1286-1291
7. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, FouadTerazi F, Victor RG 1992 Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918
8. Covic A, Goldsmith DJA, Georgescu G, Venning MC, Ackrill P 1996 Echocardiographic findings in long-term, long-hour hemodialysis patients. Clin Nephrol 45: 104-110
9. Degoulet P, Legrain M, Reach J, Aime F, Devriez C, Rojas P, Jacobs C 1982 Mortality risk factors in patients treated by chronic hemodialysis. Nephron 31: 103-110
10. Del Greco F, Davies WA, Simon NM, Huang C, Krumlovsky FA 1975 Hypertension of chronic renal failure. Role of sodium and the renal pressor system. Kidney Int 75: 176-183
11. Diamond SM, Henrich WL 1986 Hypertension in dialysis patients. Int J Artif Organs 9: 213
12. Kamper AL, Strandgaard S, Leyssac PP 1992 Effect of enalapril on the progression of chronic renal failure. Am J Hypertens 5: 423-430
13. Laurent G 1997 How to keep the dialysis patients normotensive? What is the secret of Tassin? Nephrol Dial Transplant 12: 1104
14. Lins RL, Elseviers M, Rogiers P, Van Hoeyweghen RJ, De Raedt H, Zachee P, Daelemans RA 1997 Importance of volume factors in dialysis related hypertension. Clin Nephrol 48: 29-33
15. Mann JFE, Reisch C, Ritz E 1990 Use of angiotensin converting enzyme inhibitors for the preservation of kidney function. Nephron 55 (Suppl 1): 38-42
16. Ok E, Akcicek F, Dorhout Mees EJ, Basci A, Kursat S, Unsal A 1995 Malignant hypertension in a haemodialysis patient treated by ultrafiltration. Nephrol Dial Transplant 10: 2124-2125
17. Raine AEG, Margreiter R, Brunner FP, Ehrich JHH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderabano F 1992 Report on management of renal failure in Europe, XXII, 1991 Nephrol Dial Transplant 7 (Suppl 2): 7-35
18. Ritz E, Keller Christine, Bergis KH 1996 Nephropathy of type II diabetes mellitus. Nephrol Dial Transplant 11 (Suppl 9): 38-44
19. Rodicio JL, Alcazar JM, Ruilope LM 1990 Influence of converting enzyme inhibition on glomerular filtration and proteinuria. Kidney Int 38: 590-594
20. Rodicio JL, Campo C, Ruilope LM 1995 Renal effects of calcium antagonists. Nephrol Dial Transplant 10(Suppl 9): 17-22
21. Romero JC, Raij L, Granger JP, Ruilope LM, Rodicio JL 1987 Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 10: 140-151
22. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, Swales J 1993 Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 306: 983-987
23. Silberberg JS, Barre PE, Prichard SS, Sniderman AD 1989 Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int 36: 286-290
24. Swales JD 1994 Pharmacological treatment of hypertension. Lancet 344: 380-385
25. US Recombinant Human Erythropoietin Prednalysis Study Group 1991 Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18: 50-59
26. Vertes V, Cangiano JL, Berman LB, Gould A 1969 Hypertension in end-stage renal disease. N Engl J Med 280: 978-981
27. Weidmann P, Maxwell MH, Lupu AN 1973 Plasma aldosterone in terminal renal failure. Ann Intern Med 78: 13-18
28. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R 1992 Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42: 452-458